PMID- 20005409
OWN - NLM
STAT- MEDLINE
DCOM- 20100423
LR  - 20151119
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 41
IP  - 10
DP  - 2009 Dec
TI  - Bortezomib successfully reverses early recurrence of light-chain deposition 
      disease in a renal allograft: a case report.
PG  - 4407-10
LID - 10.1016/j.transproceed.2009.10.005 [doi]
AB  - Light-Chain Deposition Disease (LCDD) frequently recurs after renal 
      transplantation, displaying a pernicious course. Herein we have described a 
      39-year-old Caucasian man with a history of immunoglobulin G-kappa multiple 
      myeloma who failed two chemotherapy regimens, but ultimately responded to the 
      combination of thalidomide, bortezomib, and dexamethasone followed by high-dose 
      melphalan and autologous stem cell transplantation 3 years prior to 
      transplantation, during which time he showed no evidence of persistent or 
      recurrent disease. At 3 days following spousal living related renal 
      transplantation, he displayed a rapid deterioration of renal function requiring 
      dialysis therapy. This episode failed to respond to empiric antirejection therapy 
      including anti-thymocyte globulin, plasmapheresis, and anti-CD20 monoclonal 
      antibody. Increasing evidence suggested recurrence of LCDD, including positive 
      immunofluorescence staining of basement membranes and vessels for kappa light 
      chains as well as free kappa light chains in his urine and serum. Following 
      suspension of sirolimus, he was initiated on and responded to bortezomib (1.3 
      mg/m(2)) with discontinuation of dialysis within 3 weeks and progressively 
      improving renal function. His maintenance therapy, in addition to six 2-week-long 
      cycles of bortezomib separated by 1-week rest periods, includes cyclosporine (50 
      mg twice daily), prednisone (10 mg daily), and curcumin (9 g daily). In sum, 
      bortezomib rescue therapy salvaged a spousal renal transplant afflicted with 
      recurrent LCDD.
FAU - Kaposztas, Z
AU  - Kaposztas Z
AD  - Department of Surgery, University of Texas Medical School at Houston, Houston, 
      Texas 77030, USA.
FAU - Kahan, B D
AU  - Kahan BD
FAU - Katz, S M
AU  - Katz SM
FAU - Van Buren, C T
AU  - Van Buren CT
FAU - Cherem, L
AU  - Cherem L
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Boronic Acids)
RN  - 0 (Pyrazines)
RN  - 69G8BD63PP (Bortezomib)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Adult
MH  - Antilymphocyte Serum/*therapeutic use
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Boronic Acids/*therapeutic use
MH  - Bortezomib
MH  - Humans
MH  - Kidney Failure, Chronic/etiology/surgery
MH  - Kidney Transplantation/adverse effects/*pathology
MH  - Male
MH  - Melphalan/therapeutic use
MH  - Multiple Myeloma/drug therapy/*pathology/surgery
MH  - Paraproteinemias/*complications
MH  - Pyrazines/*therapeutic use
MH  - Recurrence
MH  - *Stem Cell Transplantation
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 2009/12/17 06:00
MHDA- 2010/04/24 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/04/24 06:00 [medline]
AID - S0041-1345(09)01580-2 [pii]
AID - 10.1016/j.transproceed.2009.10.005 [doi]
PST - ppublish
SO  - Transplant Proc. 2009 Dec;41(10):4407-10. doi: 
      10.1016/j.transproceed.2009.10.005.